Lack of significant association between CYP1A1 T3801C polymorphism and breast cancer risk: a meta-analysis involving 25,087 subjects
Breast cancer is the most prevalent cancer in the world, which is a major public health challenge. To date, many publications have evaluated the correlation between Cytochrome P450 1A1 (CYP1A1) T3801C polymorphism and breast cancer risk. However, the results remain inconclusive. In order to derive a more precise estimation of the association, a meta-analysis was performed in this study. By searching Medline, PubMed, and ISI Web of Knowledge databases, 23 studies including 10,520 cases and 14,567 controls were collected for CYP1A1 T3801C polymorphism. The strength of association between CYP1A1 T3801C polymorphism and breast cancer risk was assessed by calculating crude ORs with 95% CIs. The pooled ORs were performed for codominant model, dominant model, and recessive model, respectively. Overall, no significant associations between CYP1A1 T3801C polymorphism and breast cancer susceptibility were found for TT versus CC (OR = 0.93; 95% CI: 0.72–1.19), TC versus CC (OR = 0.95; 95% CI: 0.79–1.14), TT + TC versus CC (OR = 0.93; 95% CI: 0.75–1.15), and TT versus TC + CC (OR = 0.99; 95% CI: 0.87–1.13). In the stratified analysis by ethnicity, menopausal status, and source of controls, no significant associations were detected in all genetic models. In conclusion, this meta-analysis provides strong evidence that CYP1A1 T3801C polymorphism is not associated with breast cancer risk.
KeywordsCYP1A1 Polymorphism Breast cancer Meta-analysis
This study was supported by national 973 programs of China grants 2004CB518605, the national 863 project of China grants 2006AA020501, and the national key sci-tech special project of China grants 2008ZX10002-020. We thank Li-Xin Qiu for revising the manuscript.
- 13.Hefler LA, Tempfer CB, Grimm C, Lebrecht A, Ulbrich E, Heinze G, Leodolter S, Schneeberger C, Mueller MW, Muendlein A, Koelbl H (2004) Estrogen-metabolizing gene polymorphisms in the assessment of breast carcinoma risk and fibroadenoma risk in Caucasian women. Cancer 101:264–269CrossRefPubMedGoogle Scholar
- 23.The MARIE-GENICA Consortium on Genetic Susceptibility for Menopausal Hormone Therapy Related Breast Cancer Risk (2009) Genetic polymorphisms in phase I and phase II enzymes and breast cancer risk associated with menopausal hormone therapy in postmenopausal women. Breast Cancer Res Treat 19:463–474Google Scholar
- 25.Shimada N, Iwasaki M, Kasuga Y, Yokoyama S, Onuma H, Nishimura H, Kusama R, Hamada GS, Nishimoto IN, Iyeyasu H, Motola J Jr, Laginha FM, Kurahashi N, Tsugane S (2009) Genetic polymorphisms in estrogen metabolism and breast cancer risk in case-control studies in Japanese, Japanese Brazilians and non-Japanese Brazilians. J Hum Genet 54:209–215CrossRefPubMedGoogle Scholar
- 26.Syamala VS, Syamala V, Sheeja VR, Kuttan R, Balakrishnan R, Ankathil R (2009) Possible risk modification by polymorphisms of estrogen metabolizing genes in familial breast cancer susceptibility in an Indian population. Cancer Investig. doi: 10.3109/07357900902744494
- 29.Justenhoven C, Hamann U, Schubert F, Zapatka M, Pierl CB, Rabstein S, Selinski S, Mueller T, Ickstadt K, Gilbert M, Ko YD, Baisch C, Pesch B, Harth V, Bolt HM, Vollmert C, Illig T, Eils R, Dippon J, Brauch H (2008) Breast cancer: a candidate gene approach across the estrogen metabolic pathway. Breast Cancer Res Treat 108:137–149CrossRefPubMedGoogle Scholar
- 35.Tobias A (1998) Assessing the influence of a single study in the meta-analysis estimate. Stata Tech Bull 8:15–17Google Scholar